Alopecia Areata
Conditions
Keywords
severe
Brief summary
The aim of our study was to retrospectively assess the efficacy and safety of systemic treatments in patients with alopecia areata, by recruiting cases from the HUGO network (Hôpitaux Universitaires du Grand Ouest), a network of 5 hospitals : Brest, Nantes, Rennes, Angers and Tours.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patient with severe alopecia * Has received at least one systemic treatment for at least 3 months (among methotrexate, intravenous or oral corticosteroid therapy, Ciclosporin, UVA/UVB phototherapy) * Patient affiliated to a social security scheme * Age greater than or equal to 18 years
Exclusion criteria
* Patients under legal protection (guardianship, curatorship, etc.) * Refusal to participate * Other cause of alopecia * Follow-up less than 3 months * Age under 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Short-term efficacy and security of systemic treatments | From January 2010 to December 2020 | Response rates including complete response or partial response or no response for each modality of treatment. and Side effects rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Long-term efficacy of systemic treatments | From January 2010 to December 2020 | Among responders (CR and PR), the maintained response rate and relapse rate |
Countries
France
Outcome results
None listed